Automation Platform EntroGen offers automated nucleic acid extraction through genomic interpretation with proprietary software embedded in the workflow, enabling labs to streamline oncology and hematology workflows and scale operations. This turnkey platform, anchored by the FDA-approved CRCdx product, creates a compelling entry point for labs seeking regulatory-grade, end-to-end solutions.

Lung Cancer Expansion The company is developing somatic mutation kits for lung cancer to guide targeted therapies, presenting an opportunity to partner with pharmacological developers for companion diagnostics or to expand panels into additional oncology indications via lab deployments.

Regulatory Edge CRCdx's FDA-approved status provides regulatory credibility when engaging hospital systems, reference labs, and payers, enabling faster adoption and easier credentialing for clinical workflows.

SMB Growth With a smaller employee footprint, EntroGen can benefit from regional distributors, CRO partnerships, and hospital networks that need scalable, cost-efficient, and maintainable solutions with strong support requirements.

Embedded Software The proprietary software integrated across the workflow is ripe for licensing, LIMS/HIS/EHR integrations, and cloud analytics, offering a pathway to expand revenue via software services and data-driven diagnostics.